Akanda Corp. Sells Subsidiary, Pays $446K Finder's Fee
Ticker: AKAN · Form: 6-K · Filed: Apr 11, 2024 · CIK: 1888014
| Field | Detail |
|---|---|
| Company | Akanda Corp. (AKAN) |
| Form Type | 6-K |
| Filed Date | Apr 11, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Key Dollar Amounts | $446,250 |
| Sentiment | neutral |
Sentiment: neutral
Topics: divestiture, subsidiary-sale, fees
TL;DR
Akanda sold RPK Biopharma, paid $446k to Cannera Holdings.
AI Summary
On April 11, 2024, Akanda Corp. announced the closing of the sale of its indirect wholly-owned Portuguese subsidiary, RPK Biopharma Unipessoal, Lda. In connection with this sale, Akanda Corp. paid a cash finder's fee of $446,250 to Cannera Holdings LTD.
Why It Matters
The sale of a subsidiary and associated fees indicate a strategic shift or divestment for Akanda Corp., impacting its operational structure and financial outflows.
Risk Assessment
Risk Level: medium — The sale of a subsidiary and the associated finder's fee suggest potential financial restructuring or a need for capital, which can introduce uncertainty.
Key Numbers
- $446,250 — Finder's Fee (Paid by Akanda Corp. to Cannera Holdings LTD in connection with the sale of RPK Biopharma.)
Key Players & Entities
- Akanda Corp. (company) — Seller of subsidiary
- RPK Biopharma Unipessoal, Lda (company) — Sold subsidiary
- Cannera Holdings LTD (company) — Recipient of finder's fee
- $446,250 (dollar_amount) — Finder's fee paid
- April 11, 2024 (date) — Date of announcement and closing
FAQ
What was the gross sales price of RPK Biopharma Unipessoal, Lda?
The filing states the finder's fee was 5% of the gross sales price, which amounted to $446,250. However, the gross sales price itself is not explicitly stated in this excerpt.
What is the business of RPK Biopharma Unipessoal, Lda?
The filing does not specify the business activities of RPK Biopharma Unipessoal, Lda, only that it was an indirect wholly-owned Portuguese subsidiary of Akanda Corp.
What is the relationship between Akanda Corp. and Cannera Holdings LTD?
Cannera Holdings LTD acted as a finder for the sale of RPK Biopharma Unipessoal, Lda, and received a finder's fee from Akanda Corp.
What is the significance of the sale of RPK Biopharma for Akanda Corp.?
The filing does not detail the strategic significance of the sale, but it represents a divestment of a subsidiary and an associated cash outflow for a finder's fee.
Are there any other fees or costs associated with the sale of RPK Biopharma mentioned?
The filing mentions the finder's fee of $446,250 was inclusive of taxes, but does not detail any other specific fees or costs related to the sale.
Filing Stats: 372 words · 1 min read · ~1 pages · Grade level 9.9 · Accepted 2024-04-11 13:33:04
Key Financial Figures
- $446,250 — he gross sales price or an aggregate of $446,250, inclusive of taxes to Cannera Holdings
Filing Documents
- ea0203676-6k_akanda.htm (6-K) — 12KB
- ea020367601ex99-1_akanda.htm (EX-99.1) — 12KB
- ea020367601ex99-2_akanda.htm (EX-99.2) — 14KB
- 0001213900-24-032120.txt ( ) — 40KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. AKANDA CORP. (Registrant) Date: April 11, 2024 By: /s/ Katie Field Name: Katie Field Title: Interim Chief Executive Officer and Director 2